ArticleGels (Basel, Switzerland)2026
Development and Characterization of Clindamycin-Loaded Dextran Hydrogel for Controlled Drug Release and Pathogen Inhibition.
Article in Gels (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The naturally occurring, biocompatible and biodegradable biopolymer dextran is a versatile material for the formulation of hydrogels with desirable properties for use in medicine, drug delivery, and tissue engineering applications. The distinctive structural and physicochemical characteristics, such as polymeric nature, gelling ability and excellent swelling properties, present it as an excellent biomaterial for drug delivery. This study explores the synthesis and characterization of dextran hydrogel for the encapsulation of clindamycin as an innovative approach for controlled drug delivery. The dextran hydrogel was synthesized through a simple and cost-effective method, and its swelling behavior, temperature and pH dependence, and surface morphology were investigated. The maximum equilibrium swelling ratio (73 ± 1%) of the hydrogel was observed in water at 25 °C within 120 min, and the hydrogel was found to be pH- and temperature-dependent for more precise and targeted drug delivery. Moreover, the dextran hydrogel was found to retain water for up to 18 h and remain stable for 8 days. The presence of a roughened surface with large openings/pores on the surface illustrated the high swelling capability of the synthesized hydrogel. In addition, the dextran hydrogel loaded with clindamycin demonstrated high drug loading capacity (70 ± 2%), rapid (65 ± 2%) in vitro drug release potential and pathogen-inhibitory activity against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.